Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
MagBioSense logo — Pioneering simple, one-step point-of-care diagnostics with l...

MagBioSense

Pioneering simple, one-step point-of-care diagnostics with laboratory-quality accuracy for rapid heart attack diagnosis in emergency settings

Founded 2013 Grant Total: $1.05M Health Care

General Information

Company Name MagBioSense
Founded Year 2013
Industries Health Care
Funding Stage Grant
Social

Get notified when MagBioSense moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MagBioSense

MagBioSense is a healthcare startup founded in 2013, with a focus on pioneering simple, one-step point-of-care diagnostics for rapid heart attack diagnosis in emergency settings. The company aims to provide laboratory-quality accuracy in a convenient and quick manner. MagBioSense's technology simplifies the detection process by eliminating additional steps, enabling a straightforward, single-step procedure in a clinical setting. Their primary focus is on leveraging high sensitivity detection of cardiac biomarkers for the rapid diagnosis and exclusion of heart attacks in the Emergency Department. The most recent investment, a Seed Round investment, was secured on 31 December 2015 from Roy Oron. As a private medical device company, MagBioSense is dedicated to creating innovative diagnostic tools and assays that address the critical need for accurate and swift diagnosis in emergency healthcare situations.

Taxonomy: Diagnostics, Point-of-Care Testing, Cardiac Biomarkers, Emergency Medicine, Healthcare Innovation, Diagnostic Assays, Lab-Quality Accuracy, Rapid Diagnosis, Heart Attack Detection, High Sensitivity Detection, Clinical Technology, Medical Innovation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• - 31 Dec 2015
Seed Round •••••• 1 •••• •••• 31 Dec 2015
Grant •••••• 1
Investor
14 May 2013

MagBioSense Alternatives & Competitors

MagBioSense vs
Huzhou Shenke
Huzhou Shenke

Advancing biological innovation through precision detection and standardized kits

Series B
Biopharma, Biotechnology
MagBioSense vs
Mercy BioAnalytics, Inc.
Mercy BioAnalytics, Inc. United States

We are making early stage cancer easier to find.

Series B
62 employees
Biotechnology, Health Care
MagBioSense vs
TERABAT, INC.
TERABAT, INC. United States

Harnessing the power of terawaves for real-time VOC detection across diverse industries.

Series Unknown
2-10 employees
Health Care, Manufacturing

FAQ About MagBioSense

Pioneering simple, one-step point-of-care diagnostics with laboratory-quality accuracy for rapid heart attack diagnosis in emergency settings
MagBioSense was founded in 2013.
MagBioSense operates in the following industries: Health Care.
MagBioSense has completed 3 funding rounds, raising a total of $1.05M. The latest funding stage is Grant.
Top alternatives and competitors to MagBioSense include Huzhou Shenke, Mercy BioAnalytics, Inc., TERABAT, INC., Aikeda Bio, ELWAVE. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MagBioSense and Huzhou Shenke are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MagBioSense and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy